Basilea Pharmaceutica AG Share Price
Stocks
BSLN
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Swiss Exchange
09:01:43 15/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 68.60 CHF | +3.16% |
|
+4.41% | +25.41% |
| 14/09 | Japanese Stocks Fall on AI Development Slowdown Calls; Oil Gains | MT |
| 14/09 | Asahi Kasei Unit Starts Phase Two Study of Antifungal Cresemba for Pediatric Patients in Japan | MT |
| Market Cap | 83Cr 100Cr 89Cr 75Cr 141.35Cr 9.43TCr 143.9Cr 992.16Cr 388.19Cr 4.92TCr 373.63Cr 365.71Cr 16TCr | P/E 2026 * |
15.4x | P/E 2027 * | 17.2x |
|---|---|---|---|---|---|
| Enterprise Value | 67Cr 81Cr 72Cr 61Cr 115.22Cr 7.69TCr 117.29Cr 808.74Cr 316.43Cr 4.01TCr 304.55Cr 298.1Cr 13TCr | EV / Sales 2026 * |
2.51x | EV / Sales 2027 * | 2.21x |
| Free-Float |
91.74% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| BSLN | Delayed | |
CBOE
| 0QNA | Real-time | |
|
London S.E.
| 0QNA | Delayed | |
|
Boerse Muenchen
| PK5 | Real-time | |
|
OTC Markets
| BPMUF | Delayed | |
|
Tradegate
| PK5 | Real-time | |
|
Deutsche Boerse AG
| PK5 | Delayed | |
|
Börse Stuttgart
| PK5 | Delayed |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | +3.16% | ||
| 1 week | +4.41% | ||
| Current month | -1.86% | ||
| 1 month | +4.89% | ||
| 3 months | +30.92% | ||
| 6 months | +20.77% | ||
| Current year | +25.41% |
| 1 week | 64.4 |  | 68.7 |
| 1 month | 64.1 | | 70.5 |
| Current year | 47.8 | | 70.5 |
| 1 year | 44.7 | | 70.5 |
| 3 years | 32 | | 70.5 |
| 5 years | 29.55 | | 70.5 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 19/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 10/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/05/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 29/11/2011 |
| Chairman | 71 | 09/04/2013 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 27/04/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/05/26 | Sell | -400 | 0.0030% | |||
| 13/05/26 | Sell | -1,043 | 0.0078% | |||
| 04/05/26 | Sell | 400 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.16% | +4.41% | +42.32% | +77.49% | 98Cr | |
| +0.21% | -7.67% | +61.07% | +71.32% | 6.89TCr | |
| +1.66% | +7.51% | +8.12% | +61.40% | 5.19TCr | |
| +3.14% | +7.17% | +12.48% | +41.70% | 4.87TCr | |
| +3.14% | +4.11% | +32.69% | +35.45% | 4.31TCr | |
| -1.38% | +1.44% | +285.05% | +459.29% | 4.15TCr | |
| +5.88% | +6.41% | +17.85% | +114.19% | 4TCr | |
| +1.28% | -0.76% | +12.67% | +45.10% | 3.06TCr | |
| -2.21% | -14.22% | +40.33% | -0.94% | 2.6TCr | |
| +1.87% | -2.04% | -13.57% | -7.00% | 2.23TCr | |
| Average | +1.67% | -3.46% | +49.90% | +89.80% | 3.74TCr | |
| Weighted average by Cap. | +1.57% | -3.48% | +54.44% | +97.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 27Cr 32Cr 29Cr 24Cr 46Cr 3.06TCr 47Cr 321.85Cr 125.93Cr 1.6TCr 121.2Cr 118.63Cr 5.11TCr | 28Cr 33Cr 30Cr 25Cr 47Cr 3.14TCr 48Cr 330.54Cr 129.33Cr 1.64TCr 124.48Cr 121.84Cr 5.25TCr |
| Net income | 6.87Cr 8.28Cr 7.39Cr 6.25Cr 12Cr 784.32Cr 12Cr 83Cr 32Cr 409.22Cr 31Cr 30Cr 1.31TCr | 5.83Cr 7.03Cr 6.27Cr 5.3Cr 9.98Cr 665.62Cr 10Cr 70Cr 27Cr 347.29Cr 26Cr 26Cr 1.11TCr |
| Net Debt | -15Cr -18Cr -16Cr -14Cr -26Cr -1.74TCr -27Cr -183.42Cr -72Cr -909.6Cr -69Cr -68Cr -2.91TCr | -22Cr -26Cr -23Cr -20Cr -37Cr -2.49TCr -38Cr -261.73Cr -102.41Cr -1.3TCr -99Cr -96Cr -4.15TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | CHF 68.60 | +3.16% | 43,629 |
| 14/26/14 | CHF 66.50 | +2.78% | 26,544 |
| 13/26/13 | CHF 64.70 | -1.52% | 15,702 |
| 12/26/12 | CHF 65.70 | +0.31% | 17,344 |
| 09/26/09 | CHF 65.50 | -0.30% | 23,308 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
